False-positive COVID-19 results: hidden problems and costs

  title={False-positive COVID-19 results: hidden problems and costs},
  author={E. Surkova and V. Nikolayevskyy and F. Drobniewski},
  journal={The Lancet. Respiratory Medicine},
  pages={1167 - 1168}
www.thelancet.com/respiratory Vol 8 December 202 
The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs
This systematic review summarizes evidence comparing the sensitivities for detection of SARS-CoV-2 infection between nasopharyngeal swabs and saliva samples and estimates the incremental cost perExpand
Prospective Clinical Assessments of Hospitalized Patients With Positive SARS-CoV-2 PCR Tests for Necessity of Isolation
One hundred forty-eight patients with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients were deemed noninfectious, most with evidence of prior infection, and managed on standard precautions without evidence of transmission. Expand
COVID-19: Balancing between Transmission Suppression and Immunity
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Expand
Disparity in clinical characteristics between 2019 novel coronavirus pneumonia and leptospirosis
The clinical disparities may facilitate the therapeutic management of these two diseases, and it is important to suspect leptospirosis in cases with a similar presentation of COVID-19. Expand
Is it enough for COVID-19 screening test? Limitation of swab test and general characteristics of mild symptom patients
Using the swab test alone is insufficient for screening test and discharge decision, and patients who may have positive result in the sputum test can be missed. Expand
False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives
A novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported via nucleic acid identification in December, 2019 and future avenues of research to evaluate lung tissue innate immune responses hold promise as a target for research to optimize SARS- covirus 2 and future infections’ testing accuracy. Expand
Molecular diagnostics in the era of COVID-19.
As the COVID-19 pandemic continues to escalate globally and acquires new mutations, accurate diagnostic technologies continue to play a vital role in controlling and understanding the epidemiology ofExpand
Guidelines on newly identified limitations of diagnostic tools for COVID‐19 and consequences
The limitations of available diagnostic procedures have been elaborated and plausible combination approach has been advised to contain the spread of coronavirus at the population level. Expand
Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays
Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT for SARS-CoV-2. Expand
Kinetics and seroprevalence of SARS-CoV-2 antibodies - a comparison of 3 different assays
There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used, and seropositivity at baseline differed significantly depending on the assay. Expand


Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
Correlation between successful isolation of virus in cell culture and Ct value of quantitative RT-PCR targeting E gene suggests that patients with Ct above 33–34 using the RT- PCR system are not contagious and thus can be discharged from hospital care or strict confinement for non-hospitalized patients. Expand
The findings reinforce the need for repeated testing in patients with suspicion of SARS-Cov-2 infection given that up to 29% of patients could have an initial RT-PCR false-negative result. Expand
False positives in reverse transcription PCR testing for SARS-CoV-2
The high false discovery rate that results, when prevalence is low, from false positive rates typical of RT-PCR assays of RNA viruses raises questions about the usefulness of mass testing; and indicates that across a broad range of likely prevalences, positive test results are more likely to be wrong than are negative results, contrary to public health advice about SARS-CoV-2 testing. Expand
European Centre for Disease Prevention and Control.
  • R. Evans
  • Medicine
  • Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • 2014
The European Centre for Disease Prevention and Control was set up in 2005 to strengthen Europe's defences against infectious diseases. The centre is an independent agency of the European Union and isExpand
Interpreting a covid-19 test result
The availability of the complete genome of covid-19 early in the epidemic facilitated development of tests to detect viral RNA, which enables infected individuals to be identified and isolated to reduce spread and provides knowledge of regional and national rates of infection to inform public health interventions. Expand
Interpreting a covid19 test result
  • BMJ
  • 2020
        Contamination at CDC lab delayed rollout of coronavirus tests